Micron Technology shares fell 6.1% on the day, caught in a worldwide selloff of AI-linked equities that has little to do with the company's own announcements. T ...
MoffettNathanson trimmed its target but kept buy; Needham downgraded to hold. Netflix cut its 2026 ad revenue forecast to ...
BioNTech plans to amend Phase 3 ROSETTA Breast-01 to test pumitamig with Gilead's Trodelvy instead of chemotherapy; the change needs regulatory approval.
Ocugen will report Q3 2026 results on 4 November 2026, a checkpoint on its OCU400 timeline and Roots licensing deal.
Micron shares gain 2.1% on sector recovery as a 24-hour Taoyuan strike starts and a Taichung labor agreement eases some ...
Nvidia plans telecom deployments, Google Cloud Rubin scale-up to 960,000 GPUs, and containerized AI factories via partners ...
UBTech signed a Japan distribution deal, began small U1 deliveries, and inked UAE and Xiamen C&D pacts — but only some are binding sales.
Diginex shareholders approved the Resulticks deal with 98.8% support, but closing by Oct 30 hinges on Nasdaq listing approval and lender consents.
BYD fell 5.2% premarket as October retail sales dropped, following a 2.9% decline on CATL's miss. Analysts weigh sector weakness against company-specific updates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results